Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NX-1011
- Development stage
- Discontinued
- Lead developer
- NITROX
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
NX-1011 is a small molecule drug developed by Nitrox LLC for the treatment of pulmonary arterial hypertension (PAH). It was investigated as an inhaled therapy, with clinical trials reaching up to Phase 2 before being discontinued. The precise mechanism of action for NX-1011 remains unknown, and it does not represent a novel mechanism. Its primary indication was pulmonary arterial hypertension, but it was also associated with research in nervous system diseases, cardiovascular diseases, and respiratory diseases[1][2][3]. No adverse events or approvals have been reported.
- Other names
- NX1011NX-1011NX 1011
Beyond the preview
Go deeper on NX-1011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NX-1011.